Tools to therapeutically harness the human antibody response
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The natural human antibody response is a rich source of highly specific, neutralizing and self-tolerant therapeutic reagents. Recent advances have been made in isolating and characterizing monoclonal antibodies that are generated in response to natural infection or vaccination. Studies of the human antibody response have led to the discovery of crucial epitopes that could serve as new targets in vaccine design and in the creation of potentially powerful immunotherapies. With a focus on influenza virus and HIV, herein we summarize the technological tools used to identify and characterize human monoclonal antibodies and describe how these tools might be used to fight infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480 · cited 3×
“In this way, they obtained broadly neutralizing antibodies that recognized conserved glycan-protein quarternary structures in variable loop regions of gp120 that were thought to be poor targets for broadly neutralizing antibodies owing to their mostly variable residues 27, 85, 87 .”
BackgroundAntibody Recognition of a Highly Conserved Influenza Virus Epitope
Ekiert, D. C., Bhabha, G., Elsliger, M.-A., Friesen, R. H. E., Jongeneelen, M., Throsby, M., Goudsmit, J., & Wilson, I. A. (2009) · Science · doi:10.1126/science.1171491 · Cited by 1,326 · cited 2×
“However, in 2008-2009, two important papers 74, 75 were published that determined the structure of two different broadly neutralizing antibodies specific for the HA2 subunit.”
BackgroundMaintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304
Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011) · Science · doi:10.1126/science.1205669 · Cited by 1,203
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830 · cited 2×
“In this way, they obtained broadly neutralizing antibodies that recognized conserved glycan-protein quarternary structures in variable loop regions of gp120 that were thought to be poor targets for broadly neutralizing antibodies owing to their mostly variable residues 27, 85, 87 .”
BackgroundStructural definition of a conserved neutralization epitope on HIV-1 gp120
Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S.-H., Yang, X., Zhang, M.-Y., Zwick, M. B., Arthos, J., et al. (2007) · Nature · doi:10.1038/nature05580 · Cited by 770
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Pejchal, R., Doores, K. J., Walker, L. M., Khayat, R., Huang, P.-S., Wang, S.-K., Stanfield, R. L., Julien, J.-P., Ramos, A., Crispin, M., et al. (2011) · Science · doi:10.1126/science.1213256 · Cited by 694 · cited 1×
“By using binding to the HIV spike as the only selection criterion, Scheid et al. and Mouquet et al.”
MethodSasaki, S., Sullivan, M., Narvaez, C. F., Holmes, T. H., Furman, D., Zheng, N.-Y., Nishtala, M., Wrammert, J., Smith, K., James, J. A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57834 · Cited by 300
Self-citation
Cited by
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
DeKosky, B. J., Ippolito, G. C., Deschner, R. P., Lavinder, J. J., Wine, Y., Rawlings, B. M., Varadarajan, N., Giesecke, C., Dörner, T., Andrews, S. F., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2492 · Cited by 410
Self-citationEllebedy, A. H., Jackson, K. J. L., Kissick, H. T., Nakaya, H. I., Davis, C. W., Roskin, K. M., McElroy, A. K., Oshansky, C. M., Elbein, R., Thomas, S., et al. (2016) · Nature Immunology · doi:10.1038/ni.3533 · Cited by 402
In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire
DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., & Georgiou, G. (2015) · Nature Medicine · doi:10.1038/nm.3743 · Cited by 357
Atomically accurate de novo design of antibodies with RFdiffusion
Bennett, N. R., Watson, J. L., Ragotte, R. J., Borst, A. J., See, D. L., Weidle, C., Biswas, R., Yu, Y., Shrock, E. L., Ault, R., et al. (2024) · doi:10.1101/2024.03.14.585103 · Cited by 324
“These methods are laborious, time-consuming, and can fail to produce antibodies that interact with the therapeutically relevant epitope 2 .”
Metadata
- Authors
- Wilson, P. C., & Andrews, S. F.
- Venue
- Nature Reviews Immunology
- Published
- 2012-09-25
- Volume
- 12
- Issue
- 10
- Pages
- 709-719
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2061059781
- Cited by
- 147
- References
- 9
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tools to therapeutically harness the human antibody response. https://app.cochat.ai/papers/10.1038/nri3285
- The paper
- Wilson, P. C., & Andrews, S. F. (2012). Tools to therapeutically harness the human antibody response. Nature Reviews Immunology. https://doi.org/10.1038/nri3285
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.